PDL injects $70M into Durata; Vivus to cut 20 staffers; FDA outlines proper use of Iclusig;

@FierceBiotech: Morningstar analyst ranks the top 11 pharma giants' prospects, putting GSK on top. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Novartis to chop 371 jobs, shutter research center in global R&D shakeup. Story | Follow @JohnCFierce

@DamianFierce: Medtronic looks to widen its renal denervation lead with latest trial. Article | Follow @DamianFierce

@EmilyMFierce: Scientists at startup Sage Therapeutics have discovered a molecule that could treat a wide range of CNS disorders. More | Follow @EmilyMFierce

> PDL BioPharma has agreed to provide Durata ($DRTX) with $70 million in debt financing. The biotech's lead antibiotic is dalbavancin, the subject of an NDA filed in September. Release

> Troubled Vivus ($VVUS) says it will trim its workforce, cutting 20 jobs to save cash. Story

> The FDA has spelled out how Ariad's ($ARIA) cancer drug Iclusig can still be used among patients who are not responding to other therapies. Ariad recently suspended sales of the drug after seeing a serious risk of blood clots among patients taking the drug. Release

Medical Device News

@FierceMedDev: Supreme Court to decide on Medtronic, Boston Scientific patent fight by June. Story | Follow @FierceMedDev

@MarkHFierce: Check out our latest issue of FierceDiagnostics--lots of good stuff and just sent out. Newsletter | Follow @MarkHFierce

> New PillCam approvals accelerate Given Imaging's revenue gains. More

> Medtronic looks to widen its renal denervation lead with latest trial. Story

> Direct Flow snags up to $50M to push heart valve in crowded market. Article

Pharma News

@FiercePharma: Trending now: Novartis eyes animal health sale as first slim-down move: Bloomberg. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Here's yesterday afternoon's Vivus Q3 earnings call transcript. More | Follow @CarlyHFierce

> U.K. caps drug spending, forcing pharma to curtail prices. More

> Novartis plots sales cuts in U.K. amid R&D restructuring. Story

> Will Merck be next to join Big Pharma's asset-sale parade? Article

Drug Delivery News

@MichaelGFierce: Gold nanoparticles first to deliver RNA to brain tumors. More | Follow @MichaelGFierce

> Langer lab makes synthetic 'good cholesterol' for cardiovascular drug delivery. Item

> IBM uses hydrogel to prolong delivery of Roche's Herceptin. More

> Platinum drug delivery method snuffs cancer's power source. Article

> Novo Nordisk wins FDA approval for two automated-dose insulin pens. News

> Study: Arrowhead's hep B RNAi drug could offer 'functional cure'. Report

Diagnostics News

> Cancer Dx test maker Veracyte launches successful IPO. Item

> Ariosa defeats Sequenom in prenatal testing patent battle. More

> Illumina, Natera, Ariosa tests gain contracts with CA's prenatal Dx program. Story

> AutoGenomics pulls IPO plans and mulls possible private offering instead. Article

> PerkinElmer to sell Transgenomic molecular Dx oncology tests overseas. Report

> Alere's new HIV test could gain momentum from Affordable Care Act. News

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.